Metagenomi, Inc. Common Stock (MGX) Stock Competitors & Peer Comparison
See (MGX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MGX | $1.20 | -4.00% | 45.2M | -0.52 | -$2.30 | N/A |
| VRTX | $499.65 | +1.69% | 126.8B | 26.55 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $631.81 | -0.17% | 65.1B | 13.85 | $45.63 | +0.58% |
| ARGX | $912.46 | +2.85% | 56.5B | 82.35 | $11.08 | N/A |
| RVMDW | $9.92 | +12.09% | 43.4B | -2.39 | -$4.15 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $192.62 | +5.79% | 41B | -27.24 | -$7.07 | N/A |
| ALNY | $293.52 | +0.74% | 39.2B | 52.89 | $5.55 | N/A |
| ONC | $289.99 | +3.61% | 31B | 64.87 | $4.47 | N/A |
Stock Comparison
MGX vs VRTX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, VRTX has a market cap of 126.8B. Regarding current trading prices, MGX is priced at $1.20, while VRTX trades at $499.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas VRTX's P/E ratio is 26.55. In terms of profitability, MGX's ROE is -0.51%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, MGX is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check VRTX's competition here
MGX vs VRNA Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, MGX is priced at $1.20, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas VRNA's P/E ratio is -102.80. In terms of profitability, MGX's ROE is -0.51%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, MGX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check VRNA's competition here
MGX vs REGN Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, REGN has a market cap of 65.1B. Regarding current trading prices, MGX is priced at $1.20, while REGN trades at $631.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas REGN's P/E ratio is 13.85. In terms of profitability, MGX's ROE is -0.51%, compared to REGN's ROE of +0.14%. Regarding short-term risk, MGX is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check REGN's competition here
MGX vs ARGX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, ARGX has a market cap of 56.5B. Regarding current trading prices, MGX is priced at $1.20, while ARGX trades at $912.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas ARGX's P/E ratio is 82.35. In terms of profitability, MGX's ROE is -0.51%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, MGX is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ARGX's competition here
MGX vs RVMDW Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, RVMDW has a market cap of 43.4B. Regarding current trading prices, MGX is priced at $1.20, while RVMDW trades at $9.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas RVMDW's P/E ratio is -2.39. In terms of profitability, MGX's ROE is -0.51%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, MGX is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for MGX.Check RVMDW's competition here
MGX vs SGEN Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, MGX is priced at $1.20, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas SGEN's P/E ratio is -57.19. In terms of profitability, MGX's ROE is -0.51%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, MGX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check SGEN's competition here
MGX vs RVMD Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, RVMD has a market cap of 41B. Regarding current trading prices, MGX is priced at $1.20, while RVMD trades at $192.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas RVMD's P/E ratio is -27.24. In terms of profitability, MGX's ROE is -0.51%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, MGX is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check RVMD's competition here
MGX vs ALNY Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, ALNY has a market cap of 39.2B. Regarding current trading prices, MGX is priced at $1.20, while ALNY trades at $293.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas ALNY's P/E ratio is 52.89. In terms of profitability, MGX's ROE is -0.51%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, MGX is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ALNY's competition here
MGX vs ONC Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, ONC has a market cap of 31B. Regarding current trading prices, MGX is priced at $1.20, while ONC trades at $289.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas ONC's P/E ratio is 64.87. In terms of profitability, MGX's ROE is -0.51%, compared to ONC's ROE of +0.12%. Regarding short-term risk, MGX is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ONC's competition here
MGX vs MRNA Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, MRNA has a market cap of 27.7B. Regarding current trading prices, MGX is priced at $1.20, while MRNA trades at $69.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas MRNA's P/E ratio is -8.55. In terms of profitability, MGX's ROE is -0.51%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, MGX is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check MRNA's competition here
MGX vs ROIV Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, ROIV has a market cap of 25B. Regarding current trading prices, MGX is priced at $1.20, while ROIV trades at $34.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas ROIV's P/E ratio is -38.54. In terms of profitability, MGX's ROE is -0.51%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, MGX is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ROIV's competition here
MGX vs BNTX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, BNTX has a market cap of 23.8B. Regarding current trading prices, MGX is priced at $1.20, while BNTX trades at $94.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas BNTX's P/E ratio is -20.40. In terms of profitability, MGX's ROE is -0.51%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, MGX is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check BNTX's competition here
MGX vs UTHR Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, UTHR has a market cap of 23.1B. Regarding current trading prices, MGX is priced at $1.20, while UTHR trades at $544.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas UTHR's P/E ratio is 20.12. In terms of profitability, MGX's ROE is -0.51%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, MGX is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check UTHR's competition here
MGX vs INCY Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, INCY has a market cap of 22.9B. Regarding current trading prices, MGX is priced at $1.20, while INCY trades at $114.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas INCY's P/E ratio is 15.41. In terms of profitability, MGX's ROE is -0.51%, compared to INCY's ROE of +0.29%. Regarding short-term risk, MGX is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check INCY's competition here
MGX vs INSM Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, INSM has a market cap of 22.7B. Regarding current trading prices, MGX is priced at $1.20, while INSM trades at $104.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas INSM's P/E ratio is -18.22. In terms of profitability, MGX's ROE is -0.51%, compared to INSM's ROE of -1.30%. Regarding short-term risk, MGX is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check INSM's competition here
MGX vs BGNE Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, MGX is priced at $1.20, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas BGNE's P/E ratio is -22.55. In terms of profitability, MGX's ROE is -0.51%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, MGX is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check BGNE's competition here
MGX vs DNA-WT Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, MGX is priced at $1.20, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, MGX's ROE is -0.51%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, MGX is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check DNA-WT's competition here
MGX vs NBIX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, NBIX has a market cap of 17.1B. Regarding current trading prices, MGX is priced at $1.20, while NBIX trades at $170.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas NBIX's P/E ratio is 24.57. In terms of profitability, MGX's ROE is -0.51%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, MGX is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check NBIX's competition here
MGX vs ASND Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, ASND has a market cap of 16.4B. Regarding current trading prices, MGX is priced at $1.20, while ASND trades at $263.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas ASND's P/E ratio is -108.97. In terms of profitability, MGX's ROE is -0.51%, compared to ASND's ROE of -56.42%. Regarding short-term risk, MGX is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ASND's competition here
MGX vs GMAB Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, GMAB has a market cap of 16B. Regarding current trading prices, MGX is priced at $1.20, while GMAB trades at $26.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas GMAB's P/E ratio is 18.72. In terms of profitability, MGX's ROE is -0.51%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, MGX is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check GMAB's competition here
MGX vs JAZZ Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, JAZZ has a market cap of 14.9B. Regarding current trading prices, MGX is priced at $1.20, while JAZZ trades at $237.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas JAZZ's P/E ratio is 18.49. In terms of profitability, MGX's ROE is -0.51%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, MGX is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check JAZZ's competition here
MGX vs BBIO Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, BBIO has a market cap of 14.1B. Regarding current trading prices, MGX is priced at $1.20, while BBIO trades at $72.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas BBIO's P/E ratio is -19.25. In terms of profitability, MGX's ROE is -0.51%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, MGX is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check BBIO's competition here
MGX vs EXEL Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, EXEL has a market cap of 13.6B. Regarding current trading prices, MGX is priced at $1.20, while EXEL trades at $54.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas EXEL's P/E ratio is 16.25. In terms of profitability, MGX's ROE is -0.51%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, MGX is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check EXEL's competition here
MGX vs IONS Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, IONS has a market cap of 13.3B. Regarding current trading prices, MGX is priced at $1.20, while IONS trades at $80.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas IONS's P/E ratio is -46.91. In terms of profitability, MGX's ROE is -0.51%, compared to IONS's ROE of -0.59%. Regarding short-term risk, MGX is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check IONS's competition here
MGX vs KRTX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, MGX is priced at $1.20, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas KRTX's P/E ratio is -28.09. In terms of profitability, MGX's ROE is -0.51%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, MGX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check KRTX's competition here
MGX vs AXSM Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, AXSM has a market cap of 12.4B. Regarding current trading prices, MGX is priced at $1.20, while AXSM trades at $241.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas AXSM's P/E ratio is -62.96. In terms of profitability, MGX's ROE is -0.51%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, MGX is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check AXSM's competition here
MGX vs MDGL Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, MDGL has a market cap of 12.2B. Regarding current trading prices, MGX is priced at $1.20, while MDGL trades at $527.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas MDGL's P/E ratio is -41.19. In terms of profitability, MGX's ROE is -0.51%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, MGX is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check MDGL's competition here
MGX vs ARWR Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, ARWR has a market cap of 11.3B. Regarding current trading prices, MGX is priced at $1.20, while ARWR trades at $80.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas ARWR's P/E ratio is -37.44. In terms of profitability, MGX's ROE is -0.51%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, MGX is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ARWR's competition here
MGX vs RNAM Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, MGX is priced at $1.20, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas RNAM's P/E ratio is -17.39. In terms of profitability, MGX's ROE is -0.51%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, MGX is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check RNAM's competition here
MGX vs KRYS Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, KRYS has a market cap of 11.1B. Regarding current trading prices, MGX is priced at $1.20, while KRYS trades at $378.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas KRYS's P/E ratio is 50.55. In terms of profitability, MGX's ROE is -0.51%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, MGX is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check KRYS's competition here
MGX vs BMRN Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, MGX is priced at $1.20, while BMRN trades at $57.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas BMRN's P/E ratio is 27.73. In terms of profitability, MGX's ROE is -0.51%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, MGX is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check BMRN's competition here
MGX vs SMMT Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, SMMT has a market cap of 11.1B. Regarding current trading prices, MGX is priced at $1.20, while SMMT trades at $14.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas SMMT's P/E ratio is -8.95. In terms of profitability, MGX's ROE is -0.51%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, MGX is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check SMMT's competition here
MGX vs TECH Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, TECH has a market cap of 11.1B. Regarding current trading prices, MGX is priced at $1.20, while TECH trades at $70.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas TECH's P/E ratio is 36.55. In terms of profitability, MGX's ROE is -0.51%, compared to TECH's ROE of +0.05%. Regarding short-term risk, MGX is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check TECH's competition here
MGX vs CYTK Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, CYTK has a market cap of 10.9B. Regarding current trading prices, MGX is priced at $1.20, while CYTK trades at $87.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas CYTK's P/E ratio is -14.97. In terms of profitability, MGX's ROE is -0.51%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, MGX is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CYTK's competition here
MGX vs RXDX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, MGX is priced at $1.20, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas RXDX's P/E ratio is -56.47. In terms of profitability, MGX's ROE is -0.51%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, MGX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check RXDX's competition here
MGX vs CORT Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, CORT has a market cap of 9.4B. Regarding current trading prices, MGX is priced at $1.20, while CORT trades at $87.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas CORT's P/E ratio is 251.11. In terms of profitability, MGX's ROE is -0.51%, compared to CORT's ROE of +0.08%. Regarding short-term risk, MGX is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CORT's competition here
MGX vs IBRX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, IBRX has a market cap of 9.2B. Regarding current trading prices, MGX is priced at $1.20, while IBRX trades at $8.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas IBRX's P/E ratio is -27.41. In terms of profitability, MGX's ROE is -0.51%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, MGX is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for MGX.Check IBRX's competition here
MGX vs HALO Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, HALO has a market cap of 9.2B. Regarding current trading prices, MGX is priced at $1.20, while HALO trades at $77.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas HALO's P/E ratio is 16.71. In terms of profitability, MGX's ROE is -0.51%, compared to HALO's ROE of +1.26%. Regarding short-term risk, MGX is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check HALO's competition here
MGX vs NUVL Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, MGX is priced at $1.20, while NUVL trades at $123.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas NUVL's P/E ratio is -21.71. In terms of profitability, MGX's ROE is -0.51%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, MGX is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check NUVL's competition here
MGX vs KYMR Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, KYMR has a market cap of 9B. Regarding current trading prices, MGX is priced at $1.20, while KYMR trades at $109.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas KYMR's P/E ratio is -30.97. In terms of profitability, MGX's ROE is -0.51%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, MGX is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check KYMR's competition here
MGX vs ALKS Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, ALKS has a market cap of 8.8B. Regarding current trading prices, MGX is priced at $1.20, while ALKS trades at $52.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas ALKS's P/E ratio is 55.29. In terms of profitability, MGX's ROE is -0.51%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, MGX is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ALKS's competition here
MGX vs IMGN Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, MGX is priced at $1.20, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas IMGN's P/E ratio is -111.55. In terms of profitability, MGX's ROE is -0.51%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, MGX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check IMGN's competition here
MGX vs TGTX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, TGTX has a market cap of 8.5B. Regarding current trading prices, MGX is priced at $1.20, while TGTX trades at $55.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas TGTX's P/E ratio is 19.15. In terms of profitability, MGX's ROE is -0.51%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, MGX is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check TGTX's competition here
MGX vs BPMC Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, MGX is priced at $1.20, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas BPMC's P/E ratio is -51.58. In terms of profitability, MGX's ROE is -0.51%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, MGX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check BPMC's competition here
MGX vs PCVX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, PCVX has a market cap of 8.3B. Regarding current trading prices, MGX is priced at $1.20, while PCVX trades at $57.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas PCVX's P/E ratio is -8.39. In terms of profitability, MGX's ROE is -0.51%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, MGX is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check PCVX's competition here
MGX vs CERE Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, MGX is priced at $1.20, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas CERE's P/E ratio is -16.47. In terms of profitability, MGX's ROE is -0.51%, compared to CERE's ROE of -0.72%. Regarding short-term risk, MGX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CERE's competition here
MGX vs APGE Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, APGE has a market cap of 8.2B. Regarding current trading prices, MGX is priced at $1.20, while APGE trades at $132.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas APGE's P/E ratio is -30.63. In terms of profitability, MGX's ROE is -0.51%, compared to APGE's ROE of -0.33%. Regarding short-term risk, MGX is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check APGE's competition here
MGX vs IMVT Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, MGX is priced at $1.20, while IMVT trades at $38.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas IMVT's P/E ratio is -14.42. In terms of profitability, MGX's ROE is -0.51%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, MGX is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check IMVT's competition here
MGX vs PTGX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, PTGX has a market cap of 7.8B. Regarding current trading prices, MGX is priced at $1.20, while PTGX trades at $121.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas PTGX's P/E ratio is -67.20. In terms of profitability, MGX's ROE is -0.51%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, MGX is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check PTGX's competition here
MGX vs RYTM Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, RYTM has a market cap of 7.5B. Regarding current trading prices, MGX is priced at $1.20, while RYTM trades at $110.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas RYTM's P/E ratio is -35.16. In terms of profitability, MGX's ROE is -0.51%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, MGX is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check RYTM's competition here
MGX vs MTSR Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, MGX is priced at $1.20, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas MTSR's P/E ratio is -23.58. In terms of profitability, MGX's ROE is -0.51%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, MGX is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check MTSR's competition here
MGX vs PRAX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, PRAX has a market cap of 7.4B. Regarding current trading prices, MGX is priced at $1.20, while PRAX trades at $350.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas PRAX's P/E ratio is -26.18. In terms of profitability, MGX's ROE is -0.51%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, MGX is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for MGX.Check PRAX's competition here
MGX vs MRUS Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, MGX is priced at $1.20, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas MRUS's P/E ratio is -17.05. In terms of profitability, MGX's ROE is -0.51%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, MGX is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check MRUS's competition here
MGX vs PTCT Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, PTCT has a market cap of 6.8B. Regarding current trading prices, MGX is priced at $1.20, while PTCT trades at $81.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas PTCT's P/E ratio is -35.01. In terms of profitability, MGX's ROE is -0.51%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, MGX is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check PTCT's competition here
MGX vs ACLX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, MGX is priced at $1.20, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas ACLX's P/E ratio is -28.27. In terms of profitability, MGX's ROE is -0.51%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, MGX is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ACLX's competition here
MGX vs LQDA Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, LQDA has a market cap of 6.7B. Regarding current trading prices, MGX is priced at $1.20, while LQDA trades at $75.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas LQDA's P/E ratio is 536.57. In terms of profitability, MGX's ROE is -0.51%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, MGX is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for MGX.Check LQDA's competition here
MGX vs COGT Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, COGT has a market cap of 6.6B. Regarding current trading prices, MGX is priced at $1.20, while COGT trades at $38.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas COGT's P/E ratio is -18.36. In terms of profitability, MGX's ROE is -0.51%, compared to COGT's ROE of -0.83%. Regarding short-term risk, MGX is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check COGT's competition here
MGX vs SRRK Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, SRRK has a market cap of 6.6B. Regarding current trading prices, MGX is priced at $1.20, while SRRK trades at $54.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas SRRK's P/E ratio is -15.31. In terms of profitability, MGX's ROE is -0.51%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, MGX is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check SRRK's competition here
MGX vs RETA Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, MGX is priced at $1.20, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas RETA's P/E ratio is -66.29. In terms of profitability, MGX's ROE is -0.51%, compared to RETA's ROE of +0.47%. Regarding short-term risk, MGX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check RETA's competition here
MGX vs CGON Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, CGON has a market cap of 6.5B. Regarding current trading prices, MGX is priced at $1.20, while CGON trades at $73.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas CGON's P/E ratio is -31.64. In terms of profitability, MGX's ROE is -0.51%, compared to CGON's ROE of -0.23%. Regarding short-term risk, MGX is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CGON's competition here
MGX vs ABVX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, ABVX has a market cap of 6.3B. Regarding current trading prices, MGX is priced at $1.20, while ABVX trades at $96.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas ABVX's P/E ratio is -50.29. In terms of profitability, MGX's ROE is -0.51%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, MGX is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ABVX's competition here
MGX vs LGND Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, LGND has a market cap of 6.3B. Regarding current trading prices, MGX is priced at $1.20, while LGND trades at $314.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas LGND's P/E ratio is 37.65. In terms of profitability, MGX's ROE is -0.51%, compared to LGND's ROE of +0.16%. Regarding short-term risk, MGX is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check LGND's competition here
MGX vs CNTA Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, MGX is priced at $1.20, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas CNTA's P/E ratio is -22.63. In terms of profitability, MGX's ROE is -0.51%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, MGX is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CNTA's competition here
MGX vs BLTE Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, MGX is priced at $1.20, while BLTE trades at $154.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas BLTE's P/E ratio is -82.70. In terms of profitability, MGX's ROE is -0.51%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, MGX is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check BLTE's competition here
MGX vs MIRM Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, MIRM has a market cap of 6.2B. Regarding current trading prices, MGX is priced at $1.20, while MIRM trades at $123.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas MIRM's P/E ratio is -9.04. In terms of profitability, MGX's ROE is -0.51%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, MGX is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check MIRM's competition here
MGX vs ERAS Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, ERAS has a market cap of 5.7B. Regarding current trading prices, MGX is priced at $1.20, while ERAS trades at $18.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas ERAS's P/E ratio is -41.57. In terms of profitability, MGX's ROE is -0.51%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, MGX is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for MGX.Check ERAS's competition here
MGX vs CDTX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, MGX is priced at $1.20, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas CDTX's P/E ratio is -19.77. In terms of profitability, MGX's ROE is -0.51%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, MGX is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CDTX's competition here
MGX vs ABCM Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, MGX is priced at $1.20, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, MGX's ROE is -0.51%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, MGX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ABCM's competition here
MGX vs ISEE Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, MGX is priced at $1.20, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas ISEE's P/E ratio is -22.44. In terms of profitability, MGX's ROE is -0.51%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, MGX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ISEE's competition here
MGX vs SYRE Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, SYRE has a market cap of 5.4B. Regarding current trading prices, MGX is priced at $1.20, while SYRE trades at $90.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas SYRE's P/E ratio is -43.35. In terms of profitability, MGX's ROE is -0.51%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, MGX is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check SYRE's competition here
MGX vs LEGN Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, LEGN has a market cap of 5.4B. Regarding current trading prices, MGX is priced at $1.20, while LEGN trades at $29.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas LEGN's P/E ratio is -43.22. In terms of profitability, MGX's ROE is -0.51%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, MGX is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check LEGN's competition here
MGX vs CRSP Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, MGX is priced at $1.20, while CRSP trades at $56.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas CRSP's P/E ratio is -11.03. In terms of profitability, MGX's ROE is -0.51%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, MGX is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CRSP's competition here
MGX vs TVTX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, TVTX has a market cap of 5.4B. Regarding current trading prices, MGX is priced at $1.20, while TVTX trades at $58.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas TVTX's P/E ratio is -265.00. In terms of profitability, MGX's ROE is -0.51%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, MGX is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check TVTX's competition here
MGX vs APLS Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, MGX is priced at $1.20, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas APLS's P/E ratio is 38.35. In terms of profitability, MGX's ROE is -0.51%, compared to APLS's ROE of +0.40%. Regarding short-term risk, MGX is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check APLS's competition here
MGX vs CAI Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, CAI has a market cap of 5.2B. Regarding current trading prices, MGX is priced at $1.20, while CAI trades at $18.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas CAI's P/E ratio is -100.77. In terms of profitability, MGX's ROE is -0.51%, compared to CAI's ROE of +0.06%. Regarding short-term risk, MGX is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CAI's competition here
MGX vs MANE Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, MANE has a market cap of 5.2B. Regarding current trading prices, MGX is priced at $1.20, while MANE trades at $123.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas MANE's P/E ratio is -39.29. In terms of profitability, MGX's ROE is -0.51%, compared to MANE's ROE of -0.95%. Regarding short-term risk, MGX is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check MANE's competition here
MGX vs DFTX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, DFTX has a market cap of 5.1B. Regarding current trading prices, MGX is priced at $1.20, while DFTX trades at $46.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas DFTX's P/E ratio is N/A. In terms of profitability, MGX's ROE is -0.51%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, MGX is more volatile compared to DFTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check DFTX's competition here
MGX vs CELC Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, CELC has a market cap of 5B. Regarding current trading prices, MGX is priced at $1.20, while CELC trades at $102.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas CELC's P/E ratio is -26.29. In terms of profitability, MGX's ROE is -0.51%, compared to CELC's ROE of -2.45%. Regarding short-term risk, MGX is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CELC's competition here
MGX vs TERN Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, MGX is priced at $1.20, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas TERN's P/E ratio is -51.41. In terms of profitability, MGX's ROE is -0.51%, compared to TERN's ROE of -0.20%. Regarding short-term risk, MGX is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check TERN's competition here
MGX vs XENE Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, XENE has a market cap of 4.7B. Regarding current trading prices, MGX is priced at $1.20, while XENE trades at $60.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas XENE's P/E ratio is -12.79. In terms of profitability, MGX's ROE is -0.51%, compared to XENE's ROE of -0.49%. Regarding short-term risk, MGX is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check XENE's competition here
MGX vs VKTX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, VKTX has a market cap of 4.6B. Regarding current trading prices, MGX is priced at $1.20, while VKTX trades at $39.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas VKTX's P/E ratio is -9.55. In terms of profitability, MGX's ROE is -0.51%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, MGX is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check VKTX's competition here
MGX vs FOLD Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, MGX is priced at $1.20, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas FOLD's P/E ratio is -161.00. In terms of profitability, MGX's ROE is -0.51%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, MGX is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check FOLD's competition here
MGX vs AKRO Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, MGX is priced at $1.20, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas AKRO's P/E ratio is -14.57. In terms of profitability, MGX's ROE is -0.51%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, MGX is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check AKRO's competition here
MGX vs ALPN Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, MGX is priced at $1.20, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas ALPN's P/E ratio is -101.52. In terms of profitability, MGX's ROE is -0.51%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, MGX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ALPN's competition here
MGX vs EWTX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, EWTX has a market cap of 4.4B. Regarding current trading prices, MGX is priced at $1.20, while EWTX trades at $40.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas EWTX's P/E ratio is -24.65. In terms of profitability, MGX's ROE is -0.51%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, MGX is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check EWTX's competition here
MGX vs ACAD Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, MGX is priced at $1.20, while ACAD trades at $25.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas ACAD's P/E ratio is 12.35. In terms of profitability, MGX's ROE is -0.51%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, MGX is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ACAD's competition here
MGX vs OPT Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, MGX is priced at $1.20, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas OPT's P/E ratio is -1.52. In terms of profitability, MGX's ROE is -0.51%, compared to OPT's ROE of +1.09%. Regarding short-term risk, MGX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check OPT's competition here
MGX vs MRTX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, MGX is priced at $1.20, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas MRTX's P/E ratio is -4.82. In terms of profitability, MGX's ROE is -0.51%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, MGX is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check MRTX's competition here
MGX vs DNLI Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, DNLI has a market cap of 4.1B. Regarding current trading prices, MGX is priced at $1.20, while DNLI trades at $25.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas DNLI's P/E ratio is -8.99. In terms of profitability, MGX's ROE is -0.51%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, MGX is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check DNLI's competition here
MGX vs TNGX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, TNGX has a market cap of 4.1B. Regarding current trading prices, MGX is priced at $1.20, while TNGX trades at $32.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas TNGX's P/E ratio is -39.23. In terms of profitability, MGX's ROE is -0.51%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, MGX is more volatile compared to TNGX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check TNGX's competition here
MGX vs DNTH Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, DNTH has a market cap of 4B. Regarding current trading prices, MGX is priced at $1.20, while DNTH trades at $95.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas DNTH's P/E ratio is -23.17. In terms of profitability, MGX's ROE is -0.51%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, MGX is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check DNTH's competition here
MGX vs NAMSW Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, NAMSW has a market cap of 4B. Regarding current trading prices, MGX is priced at $1.20, while NAMSW trades at $21.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas NAMSW's P/E ratio is -12.06. In terms of profitability, MGX's ROE is -0.51%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, MGX is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for MGX.Check NAMSW's competition here
MGX vs NAMS Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, NAMS has a market cap of 4B. Regarding current trading prices, MGX is priced at $1.20, while NAMS trades at $33.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas NAMS's P/E ratio is -21.30. In terms of profitability, MGX's ROE is -0.51%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, MGX is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check NAMS's competition here
MGX vs CRNX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, MGX is priced at $1.20, while CRNX trades at $36.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas CRNX's P/E ratio is -7.20. In terms of profitability, MGX's ROE is -0.51%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, MGX is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CRNX's competition here
MGX vs CPRX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, MGX is priced at $1.20, while CPRX trades at $31.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas CPRX's P/E ratio is 11.32. In terms of profitability, MGX's ROE is -0.51%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, MGX is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CPRX's competition here
MGX vs TLX Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, MGX is priced at $1.20, while TLX trades at $11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas TLX's P/E ratio is -615.13. In terms of profitability, MGX's ROE is -0.51%, compared to TLX's ROE of -0.02%. Regarding short-term risk, MGX is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check TLX's competition here
MGX vs RYZB Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, MGX is priced at $1.20, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas RYZB's P/E ratio is -57.86. In terms of profitability, MGX's ROE is -0.51%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, MGX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check RYZB's competition here
MGX vs CBAY Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, MGX is priced at $1.20, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas CBAY's P/E ratio is -32.81. In terms of profitability, MGX's ROE is -0.51%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, MGX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check CBAY's competition here
MGX vs ELVN Comparison July 2026
MGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGX stands at 45.2M. In comparison, ELVN has a market cap of 3.6B. Regarding current trading prices, MGX is priced at $1.20, while ELVN trades at $50.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGX currently has a P/E ratio of -0.52, whereas ELVN's P/E ratio is -30.45. In terms of profitability, MGX's ROE is -0.51%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, MGX is more volatile compared to ELVN. This indicates potentially higher risk in terms of short-term price fluctuations for MGX.Check ELVN's competition here